PMID- 35120770
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20220915
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 83
IP  - 10
DP  - 2022 Oct
TI  - Tools for optimizing risk assessment in hematopoietic cell transplant - What can 
      we get away with?
PG  - 704-711
LID - S0198-8859(22)00013-1 [pii]
LID - 10.1016/j.humimm.2022.01.010 [doi]
AB  - Unrelated allogeneic hematopoietic cell transplant (HCT) is a critical modality 
      to treat hematologic malignancies. The current objective of donor selection is to 
      match donor and recipient at the HLA (human leukocyte antigen) peptide-binding 
      region which should lower the risk of graft-versus-host disease. However, 
      depending on the patient's ethnicity/race, finding a matched donor is 
      challenging, especially for HLA-DPB1 which is due to the weak linkage 
      disequilibrium between HLA-DPB1 and the other HLA class II loci. Recent evidence, 
      on the molecular level, has shown that certain HLA mismatches carry lower 
      clinical risk. More specifically, there is an increasing understanding of 
      polymorphisms of the innate and adaptive immune systems and their impact on 
      transplant outcomes, allowing us to expand our "toolkit" for optimization of 
      donor selection in HCT. Therefore, in this review we discuss matching strategies 
      based on comparing donor and recipient polymorphisms that may influence innate 
      and adaptive immune response genes in allorecognition and the role of single 
      nucleotide polymorphisms in non-HLA genes that have the potential for providing 
      additional tools to refine risk stratification.
CI  - Copyright (c) 2022 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Hod-Dvorai, Reut
AU  - Hod-Dvorai R
AD  - Department of Pathology, SUNY Upstate Medical University, 750 East Adams Street, 
      Suite 4721, Syracuse, NY 13210, United States. Electronic address: 
      hoddvorr@upstate.edu.
FAU - Cusick, Matthew F
AU  - Cusick MF
AD  - Department of Pathology, University of Michigan Medicine, 2800 Plymouth Rd., 
      Building 36, Ann Arbor, MI 48109, United States. Electronic address: 
      mfcusick@med.umich.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220201
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
SB  - IM
MH  - *Graft vs Host Disease/genetics/prevention & control
MH  - *Hematologic Neoplasms/therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - Risk Assessment
MH  - Unrelated Donors
OTO - NOTNLM
OT  - Alloimmune response
OT  - Innate alloimmune response
OT  - Noninherited maternal antigens
OT  - TCE - T cell epitope
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/02/06 06:00
MHDA- 2022/09/16 06:00
CRDT- 2022/02/05 05:36
PHST- 2021/11/19 00:00 [received]
PHST- 2021/12/20 00:00 [revised]
PHST- 2022/01/17 00:00 [accepted]
PHST- 2022/02/06 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
PHST- 2022/02/05 05:36 [entrez]
AID - S0198-8859(22)00013-1 [pii]
AID - 10.1016/j.humimm.2022.01.010 [doi]
PST - ppublish
SO  - Hum Immunol. 2022 Oct;83(10):704-711. doi: 10.1016/j.humimm.2022.01.010. Epub 
      2022 Feb 1.